Capitalizing on investors' interest in companies developing drugs for nonalcoholic steatohepatitis (NASH) as it awaits Phase III results for lead drug candidate elafibranor, Genfit SA went public in the US on March 26 at $20.32 per American depository share (ADS) and ended its first trading day up 9.1% at $22.17 on March 27.
Genfit Chief Operating Officer Dean Hum told Scrip that the main reason the French firm – which already trades on the Euronext in Paris – launched an IPO stateside was to establish a presence in the US and build upon its existing team in Boston ahead of the
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?